Advertisement

Pruritus

  • Jacek C. SzepietowskiEmail author
  • Adam Reich

Abstract

Pruritus is defined as an unpleasant sensation that produces a desire to scratch. By most researchers and physicians, pruritus and itch are considered as synonymous terms. Itching lasting less than 6 weeks is termed as an acute pruritus, while presenting longer than 6 weeks is defined as a chronic one. Pruritus may be limited to a certain area (localized pruritus) or involve the entire body (generalized pruritus). According to the consensus of the International Forum for the Study of Itch (IFSI), three clinical presentations may be distinguished: (1) pruritus on diseased, inflamed skin; (2) pruritus on normal, non-inflamed skin; and, finally, (3) pruritus with chronic secondary scratch lesions. Successful antipruritic therapy may be introduced, if the underlying disease is identified.

Keywords

Itching Antihistamines Dermatological pruritus Scratching 

References

  1. Desai NS, Poindexter GB, Monthrope YM, Bendeck SE, Swerlick RA, Chen SC. A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol. 2008;59:234–44.PubMedCrossRefGoogle Scholar
  2. Goutos I, Eldardiri M, Khan AA, Dziewulski P, Richardson PM. Comparative evaluation of antipruritic protocols in acute burns. The emerging value of gabapentin in the treatment of burns pruritus. J Burn Care Res. 2010;31:57–63.PubMedCrossRefGoogle Scholar
  3. Grimstad O, Sawanobori Y, Vestergaard C, Bilsborough J, Olsen UB, Grønhøj-Larsen C, Matsushima K. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol. 2009;18:35–43.PubMedCrossRefGoogle Scholar
  4. Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant. 2010;25:1251–7.PubMedCrossRefGoogle Scholar
  5. Liu Q, Weng HJ, Patel KN, Tang Z, Bai H, Steinhoff M, Dong X. The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia. Sci Signal. 2011;4:ra45.PubMedPubMedCentralGoogle Scholar
  6. Liu T, Berta T, Xu ZZ, Park CK, Zhang L, Lü N, et al. TLR3 deficiency impairs spinal cord synaptic transmission, central sensitization, and pruritus in mice. J Clin Invest. 2012;122:2195–207.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol. 1999;41:533–9.PubMedGoogle Scholar
  8. Nelson L, Vergnolle N, D’Mello C, Chapman K, Le T, Swain MG. Endogenous opioid-mediated antinociception in cholestatic mice is peripherally, not centrally, mediated. J Hepatol. 2006;44:1141–9.PubMedCrossRefGoogle Scholar
  9. Raap U, Weißmantel S, Gehring M, Eisenberg AM, Kapp A, Fölster-Holst R. IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis. Pediatr Allergy Immunol. 2012;23:285–8.PubMedCrossRefGoogle Scholar
  10. Reich A, Hrehorów E, Szepietowski JC. Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol. 2010;90:257–63.PubMedCrossRefGoogle Scholar
  11. Reich A, Ständer S, Szepietowski JC. Pruritus in the elderly. Clin Dermatol. 2011;29:15–23.PubMedCrossRefGoogle Scholar
  12. Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, Furue M, Blome C, Augustin M, Ständer S, Szepietowski JC. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol. 2012a;92:497–501.PubMedCrossRefGoogle Scholar
  13. Reich A, Mędrek K, Szepietowski JC. Four-item itch questionnaire – validation of questionnaire. Przegl Dermatol. 2012b;99:600–4.Google Scholar
  14. Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 2012;13:1020–4.PubMedCrossRefGoogle Scholar
  15. Shaw RJ, Dayal S, Good J, Bruckner AL, Joshi SV. Psychiatric medications for the treatment of pruritus. Psychosom Med. 2007;69:970–8.PubMedCrossRefGoogle Scholar
  16. Solak Y, Biyik Z, Atalay H, Gaipov A, Guney F, Turk S, et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology (Carlton). 2012;17:710–7.CrossRefGoogle Scholar
  17. Ständer S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol. 2001;44:471–8.PubMedCrossRefGoogle Scholar
  18. Ständer S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol. 2007;87: 291–4.PubMedCrossRefGoogle Scholar
  19. Ständer S, Augustin M, Reich A, Blome C, Ebata T, Phan NQ, Szepietowski JC. Pruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials. Acta Derm Venereol. 2013;93:509–14.PubMedCrossRefGoogle Scholar
  20. Szepietowski JC, Morita A, Tsuji T. Ultraviolet B induces mast cell apoptosis: a hypothetical mechanism of ultraviolet B treatment for uraemic pruritus. Med Hypotheses. 2002;58:167–70.PubMedCrossRefGoogle Scholar
  21. Szepietowski JC, Reich A, Szepietowski T. Emollients with endocannabinoids in the treatment of uremic pruritus: discussion of the therapeutic options. Ther Apher Dial. 2005;9:277–9.PubMedCrossRefGoogle Scholar
  22. Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol. 2007;127:2228–35.PubMedCrossRefGoogle Scholar
  23. Wallace M, Pappagallo M. Qutenza®: a capsaicin 8% patch for the management of postherpetic neuralgia. Expert Rev Neurother. 2011;11:15–27.PubMedCrossRefGoogle Scholar
  24. Wąsik F, Szepietowski J, Szepietowski T, Weyde W. Relief of uraemic pruritus after balneological therapy with a bath oil containing polidocanol (Balneum Hermal Plus). An open clinical study. J Dermatol Treat. 1996;7:231–3.CrossRefGoogle Scholar
  25. Weisshaar E, Gieler U, Kupfer J, Furue M, Saeki H, Yosipovitch G, International Forum on the Study of Itch. Questionnaires to assess chronic itch: a consensus paper of the special interest group of the International Forum on the Study of Itch. Acta Derm Venereol. 2012a;92:493–6.PubMedCrossRefGoogle Scholar
  26. Weisshaar E, Szepietowski JC, Darsow U, Misery L, Wallengren J, Mettang T, et al. European guideline on chronic pruritus. Acta Derm Venereol. 2012b;92:563–81.PubMedCrossRefGoogle Scholar
  27. Wilson SR, Gerhold KA, Bifolck-Fisher A, Liu Q, Patel KN, Dong X, Bautista DM. TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch. Nat Neurosci. 2011;14:595–602.PubMedPubMedCentralCrossRefGoogle Scholar
  28. Yamamoto A, Sugimoto Y. Involvement of peripheral mu opioid receptors in scratching behavior in mice. Eur J Pharmacol. 2010;649:336–41.PubMedCrossRefGoogle Scholar

Further Reading

  1. Ally MS, Gamba CS, Peng DH, Tang JY. The use of aprepitant in brachioradial pruritus. JAMA Dermatol. 2013;149:627–8.PubMedCrossRefGoogle Scholar
  2. Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivanis P. The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients. J Ren Care. 2010;36:180–5.PubMedCrossRefGoogle Scholar
  3. Barikbin B, Givrad S, Yousefi M, Eskandari F. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol. 2009;34:776–80.PubMedCrossRefGoogle Scholar
  4. Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology. 1992;102:544–9.PubMedCrossRefGoogle Scholar
  5. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med. 1995;123:161–7.PubMedCrossRefGoogle Scholar
  6. Booken N, Heck M, Nicolay JP, Klemke CD, Goerdt S, Utikal J. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011;164:665–7.PubMedGoogle Scholar
  7. Borja-Consigliere HA, López-Pestaña A, Vidal-Manceñido MJ, Tuneu-Valls A. Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma. Actas Dermosifiliogr. 2014;105:716–8.PubMedCrossRefGoogle Scholar
  8. Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol. 2003;98:2736–41.PubMedCrossRefGoogle Scholar
  9. Darsow U, Scharein E, Simon D, Walter G, Bromm B, Ring J. New aspects of itch pathophysiology: component analysis of atopic itch using the ‘Eppendorf Itch Questionnaire’. Int Arch Allergy Immunol. 2001;124:326–31.PubMedCrossRefGoogle Scholar
  10. Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2006;55:543–4.PubMedCrossRefGoogle Scholar
  11. Drake LA, Millikan LE. The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group. Arch Dermatol. 1995;131:1403–8.PubMedCrossRefGoogle Scholar
  12. Drake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group. J Am Acad Dermatol. 1994;31:613–6.PubMedCrossRefGoogle Scholar
  13. Duque MI, Yosipovitch G, Fleischer Jr AB, Willard J, Freedman BI. Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. J Am Acad Dermatol. 2005;52:519–21.PubMedCrossRefGoogle Scholar
  14. Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008;22:73–82.PubMedGoogle Scholar
  15. Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010;162:587–93.PubMedCrossRefGoogle Scholar
  16. Ezzat MH, Hasan ZE, Shaheen KY. Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring. J Eur Acad Dermatol Venereol. 2011;25:334–9.PubMedCrossRefGoogle Scholar
  17. Freitag G, Höppner T. Results of a postmarketing drug monitoring survey with a polidocanol-urea preparation for dry, itching skin. Curr Med Res Opin. 1997;13:529–37.PubMedCrossRefGoogle Scholar
  18. Furue M, Ebata T, Ikoma A, Takeuchi S, Kataoka Y, Takamori K, et al. Verbalizing extremes of the visual analogue scale for pruritus: a consensus statement. Acta Derm Venereol. 2013;93:214–5.PubMedCrossRefGoogle Scholar
  19. Gambichler T, Othlinghaus N, Tomi NS, Holland-Letz T, Boms S, Skrygan M, et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol. 2009;160:652–8.PubMedCrossRefGoogle Scholar
  20. Gao H, Zhang W, Wang Y. Acupuncture treatment for 34 cases of uremic cutaneous pruritus. J Tradit Chin Med. 2002;22:29–30. PubMed PMID: 11977515.PubMedGoogle Scholar
  21. Goldstein AT, Creasey A, Pfau R, Phillips D, Burrows LJ. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J Am Acad Dermatol. 2011;64:e99–104.PubMedCrossRefGoogle Scholar
  22. Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant. 2004;19:3137–9.PubMedCrossRefGoogle Scholar
  23. Han N, Zu JY, Chai J. Spinal bombesin-recognized neurones mediate more nonhistaminergic than histaminergic sensation of itch in mice. Clin Exp Dermatol. 2012;37:290–5.PubMedCrossRefGoogle Scholar
  24. Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol. 2004;50:889–91.PubMedCrossRefGoogle Scholar
  25. Jeffry J, Kim S, Chen ZF. Itch signaling in the nervous system. Physiology (Bethesda). 2011;26:286–92.Google Scholar
  26. Kobza BA. H1 antagonists in the management of the itch of urticarias. Skin Pharmacol. 1992;5:21–4.CrossRefGoogle Scholar
  27. Kuhn A, Gensch K, Haust M, Schneider SW, Bonsmann G, Gaebelein-Wissing N, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol. 2011;65:54–64, 64.e1–2.PubMedCrossRefGoogle Scholar
  28. Liu Q, Tang Z, Surdenikova L, Kim S, Patel KN, Kim A, et al. Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. Cell. 2009;139:1353–65.PubMedPubMedCentralCrossRefGoogle Scholar
  29. Liu T, Xu ZZ, Park CK, Berta T, Ji RR. Toll-like receptor 7 mediates pruritus. Nat Neurosci. 2010;13:1460–2.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Loosemore MP, Bordeaux JS, Bernhard JD. Gabapentin treatment for nostalgia paresthetica, a common isolated peripheral sensory neuropathy. J Eur Acad Dermatol Venereol. 2007;21:1440–1.PubMedCrossRefGoogle Scholar
  31. Majeski CJ, Johnson JA, Davison SN, Lauzon CJ. Itch Severity Scale: a self-report instrument for the measurement of pruritus severity. Br J Dermatol. 2007;156:667–73.PubMedCrossRefGoogle Scholar
  32. Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45:666–74.PubMedCrossRefGoogle Scholar
  33. Monroe EW. Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. J Am Acad Dermatol. 1989;21:135–6.PubMedCrossRefGoogle Scholar
  34. Morris V, Murphy LM, Rosenberg M, Rosenberg L, Holzer 3rd CE, Meyer 3rd WJ. Itch assessment scale for the pediatric burn survivor. J Burn Care Res. 2012;33:419–24.PubMedCrossRefGoogle Scholar
  35. Pacan P, Grzesiak M, Reich A, Szepietowski JC. Is pruritus in depression a rare phenomenon? Acta Derm Venereol. 2009;89:109–10.PubMedCrossRefGoogle Scholar
  36. Papoiu AD, Coghill RC, Kraft RA, Wang H, Yosipovitch G. A tale of two itches. Common features and notable differences in brain activation evoked by cowhage and histamine induced itch. Neuroimage. 2012;59:3611–23.PubMedCrossRefGoogle Scholar
  37. Papp KA, Papp A, Dahmer B, Clark CS. Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. J Am Acad Dermatol. 2012;67:e11–5.PubMedCrossRefGoogle Scholar
  38. Pauli-Magnus C, Klumpp S, Alscher DM, Kuhlmann U, Mettang T. Short-term efficacy of tacrolimus ointment in severe uremic pruritus. Perit Dial Int. 2000;20:802–3.PubMedGoogle Scholar
  39. Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92:502–7.PubMedCrossRefGoogle Scholar
  40. Razeghi E, Eskandari D, Ganji MR, Meysamie AP, Togha M, Khashayar P. Gabapentin and uremic pruritus in hemodialysis patients. Ren Fail. 2009;31:85–90.PubMedCrossRefGoogle Scholar
  41. Reich A, Szepietowski JC. Opioid-induced pruritus: an update. Clin Exp Dermatol. 2010;35:2–6.PubMedCrossRefGoogle Scholar
  42. Reich A, Szepietowski JC. Non-analgesic effects of opioids: peripheral opioid receptors as promising targets for future anti-pruritic therapies. Curr Pharm Des. 2012;18:6021–4.PubMedCrossRefGoogle Scholar
  43. Reich A, Szepietowski JC. Pruritus intensity assessment: challenge for clinicians. Expert Rev Dermatol. 2013;8:291–9.CrossRefGoogle Scholar
  44. Sheen MJ, Ho ST, Lee CH, Tsung YC, Chang FL. Preoperative gabapentin prevents intrathecal morphine-induced pruritus after orthopedic surgery. Anesth Analg. 2008;106:1868–72.PubMedCrossRefGoogle Scholar
  45. Siepmann D, Luger TA, Ständer S. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series. J Dtsch Dermatol Ges. 2008;6:941–6.PubMedCrossRefGoogle Scholar
  46. Siniewicz-Luzeńczyk K, Stańczyk-Przyłuska A, Zeman K. Correlation between serum interleukin-31 level and the severity of disease in children with atopic dermatitis. Post Dermatol Alergol. 2013;30:282–5.CrossRefGoogle Scholar
  47. Smith PF, Corelli RL. Doxepin in the management of pruritus associated with allergic cutaneous reactions. Ann Pharmacother. 1997;31:633–5.PubMedCrossRefGoogle Scholar
  48. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res. 2000;48:555–60.PubMedCrossRefGoogle Scholar
  49. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. The diagnostic validity of the Athens Insomnia Scale. J Psychosom Res. 2003;55:263–7.PubMedCrossRefGoogle Scholar
  50. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117:411–7.PubMedCrossRefGoogle Scholar
  51. Ständer S, Reinhardt HW, Luger TA. Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus. Hautarzt. 2006;57:801–7.PubMedCrossRefGoogle Scholar
  52. Ständer S, Böckenholt B, Schürmeyer-Horst F, Weishaupt C, Heuft G, Luger TA, Schneider G. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol. 2009;89:45–51.PubMedCrossRefGoogle Scholar
  53. Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5:e10968.PubMedPubMedCentralCrossRefGoogle Scholar
  54. Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature. 2007;448:700–3.PubMedCrossRefGoogle Scholar
  55. Sun YG, Zhao ZQ, Meng XL, Yin J, Liu XY, Chen ZF. Cellular basis of itch sensation. Science. 2009;325:1531–4.PubMedCrossRefGoogle Scholar
  56. Szepietowski J, Reich A, Białynicki-Birula R. Itching in atopic dermatitis: clinical manifestation, pathogenesis and the role of pimecrolimus in itch reduction. Dermatol Klin. 2004;6:173–6.Google Scholar
  57. Takaoka A, Arai I, Sugimoto M, Honma Y, Futaki N, Nakamura A, Nakaike S. Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis. Exp Dermatol. 2006;15:161–7.PubMedCrossRefGoogle Scholar
  58. Torres T, Fernandes I, Selores M, Alves R, Lima M. Aprepitant: evidence of its effectiveness in patients with refractory pruritus continues. J Am Acad Dermatol. 2012;66:e14–5.PubMedCrossRefGoogle Scholar
  59. Vincenzi B, Fratto ME, Santini D, Tonini G. Aprepitant against pruritus in patients with solid tumours. Support Care Cancer. 2010;18:1229–30.PubMedCrossRefGoogle Scholar
  60. Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med. 2010;363:397–8.PubMedCrossRefGoogle Scholar
  61. Wahlgren CF, Scheynius A, Hägermark O. Antipruritic effect of oral cyclosporine A in atopic dermatitis. Acta Derm Venereol. 1990;70:323–9.PubMedGoogle Scholar
  62. Wallengren J, Klinker M. Successful treatment of notalgia paresthetica with topical capsaicin: vehicle-controlled, double-blind, crossover study. J Am Acad Dermatol. 1995;32:287–9.PubMedCrossRefGoogle Scholar
  63. Yosipovitch G, Goon AT, Wee J, Chan YH, Zucker I, Goh CL. Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus. Int J Dermatol. 2002;41:212–6.PubMedCrossRefGoogle Scholar
  64. Zhao ZQ, Huo FQ, Jeffry J, Hampton L, Demehri S, et al. Chronic itch development in sensory neurons requires BRAF signaling pathways. J Clin Invest. 2013;123:4769–80.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Dermatology, Venereology and AllergologyWroclaw Medical UniversityWrocławPoland

Personalised recommendations